|
Day one - Wednesday 25 June 2008
|
8.30am | Registration & coffee
|
8.50am | Opening remarks from the chair
|
| BUSINESS STRATEGY; KEY DRIVERS AND DEVELOPMENTS |
|
9am | What are the financial sector's expectations for the oncology marketplace?
• market dynamics
• winners and losers
• critical success factors |
| |
|
9.30am | The value of the oncology drugs in development
• Review of recent deals by stages of development
• Is there space in the market for so many new products?
• Reimbursement issues
• Deal valuation |
| |
|
10am | Pricing for outcome and risk sharing: what are the next steps?
|
10.30am | Morning tea
|
11am | Value for money: a European perspective
• Who's values?
• Who's money?
• Who pays? |
| |
|
11.30am | Are biotech companies prepared to recognise the needs of oncology patients and avoid the mistakes of large pharmaceutical companies?
• How are the issues that impacting today’s medical consumers
• Understanding accomplishments and strides
• How can biotech companies could win the respect of patients
• From the bench to the bedside – translating clinical progress
• Directions in public policy and positive outcomes through collaboration with patient advocates |
| |
|
12pm | Oncology vaccines: should pharmaceutical companies welcome or avoid them?
• Cancer vaccines, tumour types and technologies
• Primary role and synergy with other modalities
• The importance of inhibiting the T-reg and suppressor cell network
• The importance of sequential design and the right drugs in treatment |
| |
|
12.30pm | Lunch
|
| TRANSLATIONAL MEDICINE AND BIOMARKERS |
|
1.30pm | Targeting DNA damage detection and repair pathways to enhance the effectiveness of cancer therapeutics
• Targeted DNA damage detection and repair pathways have become increasingly attractive targets for cancer drug discovery efforts, with several agents now in clinical trials
• Rationale and promise of such agents to provide significant improvements in the treatment of cancer |
| |
|
2pm | The utility & value of predictive response markers in oncology |
| | Dr Hans Winkler, Senior Director, Translational Research , Johnson & Johnson
|
2.30pm | The development of imaging biomarkers for drug development: the potential of molecular imaging
• In-vivo molecular imaging as an emerging discipline to the development of cancer therapies
• New and emerging quantitative functional imaging technology to look at molecular pathways
• Imaging biomarkers in early clinical trials
• Molecular imaging biomarkers potential to streamline and accelerate rational drug development in oncology |
| | Professor Patricia Price, Ralston Paterson Professor of Radiation Oncology , Christie Hospital NHS Foundation Trust & University of Manchester
|
3pm | Afternoon tea
|
3.30pm | Breakthroughs in cancer biomarker discovery using innovative strategies
• Proteomics technologies; in-depth searches and identification of novel cancer markers
• Discovery research; individual lab effort to collective efforts
• Validation studies and the relevance of novel biomarkers for early cancer detection |
| | Dr Samir Hanash, Molecular Diagnostics, Fred Hutchinson Cancer Research Center, Seattle
|
4pm | Biomarker Case study |
| |
|
4.30pm | Closing Remarks from the chair followed by networking drinks reception
|
|
Day two - Thursday 26 June 2008
|
8.30am | Registration & coffee
|
8.50am | Opening remarks from the chair
|
| EARLY CLINICAL - As exciting new products enter the clinic and are progressing through the development process, this session will examine the progress of specific products. Special attention will be p |
|
9am | Case studies on targeted therapeutics |
| | Mr Timothy L Enns, Senior Vice President, Corporate Communications & Business Development, SuperGen Inc
|
9.30am | Development of molecular markers for the differential needs of clinical trials and patient diagnostics |
| | Dr Joe Monforte, Vice President and Chief Scientific Officer, Althea Technologies
|
10am | Targeting the notch pathway |
| |
|
10.30am | Improving Timelines of Phase I Dose Finding Studies through Cohort Size Simulations for Anti-Cancer Products |
| |
|
11am | Morning tea
|
11.30am | Identification & early validation of cancer antibody targets
• target choices: inhibition of cell-surface receptors vs. immune effector targeting
• ligands and receptors: Screening the extracellular proteome for cancer-related functions
• rapid in vivo screening and validation for functionally relevant targets |
| |
|
12pm | Latest clinical results for Novartis' anti-angiogenesis treatment in early stage trials |
| |
|
12.30pm | Amgen's pipeline of targeted therapeutics
• Vectibix; developed for use in patients with advanced stage CRC
• Pivotal trial vs. best supportive care
• Predicting responders which markedly enhanced the benefit: risk ratio
• Pre-specified retrospective analysis in biomarker development
• KRAS in the predictive biomarker field
• KRAS; establishing consistency of hypothesis
• Use of EGFR antagonists |
| | Dr Roy Baynes, Vice President, Global Development, Oncology Supportive Care , Amgen
|
1pm | Lunch
|
| REGULATORY UPDATE AND REVIEW - This session will look at specific regulatory challenges that are faced by developers of oncology products it will begin with a broad review of the international arena, |
|
2pm | An Industry Perspective |
| |
|
2.30pm | The potential impact of recently approved & emerging molecular diagnostics |
| | Dr Francis Kalush, Molecular Diagnostics, Office of In Vitro Diagnostics , US Food & Drug Administration
|
3pm | Undertaking head-to-head clinical trials in phase IIb: the commercial and clinical implications of the 505 (b) (2)regulatory pathway to approval |
| |
|
3.30pm | Afternoon tea
|
| NOVEL APPROACHES FOR TARGETED THERAPIES - Targeted therapies are now common place in standard treatment regimens. Many more products are forecast to reach the market over the next few years giving so |
|
4pm | Case study: development of a systems biology designed therapeutic for the treatment of cancer |
| |
|
4.30pm | The potential of molecular pathology for targeted therapies |
| |
|
5pm | Combination therapies for oncology: targeted challenges |
| | Dr Geert Kolvenbag, Executive Director of Development, Emerging Oncology Brands, AstraZeneca
|
5pm | Closing remarks and end of conference
|
